SABS
SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.72
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +71.7%
- EBIT
- -71.7%
- EPS
- +189.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +157.2%
- EBIT
- -14.1%
- Net income
- +138.9%
- EPS
- +106.0%
- Free cash flow
- -32.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026